Otenaproxesul

Otenaproxesul
Clinical data
Other names	ATB-352
Routes of; administration	By mouth
ATC code	None;
Legal status
Legal status	US: Investigational New Drug;
Identifiers
	IUPAC name 4-Carbamothioylphenyl (2S)-2-(6-methoxy-2-naphthyl)propanoate;
CAS Number	1000700-29-7 ;
PubChem CID	25065981;
ChemSpider	32701263;
UNII	V44GCU5P5O;
ChEMBL	ChEMBL4211107;
CompTox Dashboard (EPA)	DTXSID201336751 ;
Chemical and physical data
Formula	C21H19NO3S
Molar mass	365.45 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC2=CC=C(C=C2C=C1)C(C)C(=O)OC3=CC=C(C=C3)C(N)=S;
	InChI InChI=1S/C21H19NO3S/c1-13(21(23)25-18-8-5-14(6-9-18)20(22)26)15-3-4-17-12-19(24-2)10-7-16(17)11-15/h3-13H,1-2H3,(H2,22,26)/t13-/m0/s1; Key:YCNMAPLPQYQJFC-ZDUSSCGKSA-N;

Otenaproxesul is a analgesic and anti-inflammatory drug being developed by Antibe Therapeutics. An NSAID structurally derived from naproxen, in 2016 it received approval to commence phase II clinical trials as a treatment for osteoarthritis after completing phase I clinical trials in 2015.^[2] In 2018, the drug completed trials for gastrointestinal safety, and in 2020 completed phase IIb trials on efficacy of pain reduction.^[3] Initial phase III clinical trials in 2021 failed to meet the necessary criteria to advance to the next phase.

Other in vivo studies have demonstrated a reduction in zymosan-induced pain and inflammation and cytokine-induced bone loss.^[4] Preclinical studies have also investigated the treatment of melanoma, intestinal cancer,^[5] and periodontitis.^[6]

Pharmacology

Like other NSAIDs, otenaproxesul acts as an inhibitor of the cycloxygenase (COX) enzymes, suppressing the production of prostaglandins. Additionally, it releases hydrogen sulfide in the gastrointestinal tract, reducing gastrointestinal adverse effects such as ulcers.^[7]

^ "4-Carbamothioylphenyl 2-(6-methoxynaphthalen-2-yl)propanoate". PubChem. National Institute of Health. Retrieved February 9, 2021.
^ "Otenaproxesul". IUPHAR/BPS Guide to Pharmacology. January 27, 2021.
^ "Otenaproxesul (ATB-346)". Antibe Therapeutics. 19 July 2019. Retrieved February 17, 2021.
^ "Otenaproxesul, (+/-)-". National Center for Advancing Translational Sciences. Retrieved February 9, 2021.
^ Elsheikh W, Blackler RW, Flannigan KL, Wallace JL (September 15, 2014). "Enhanced chemopreventive effects of a hydrogen sulfide-releasing anti-inflammatory drug (ATB-346) in experimental colorectal cancer". Nitric Oxide. 41: 131–7. doi:10.1016/j.niox.2014.04.006. PMID 24747869 – via PubMed.
^ Gugliandolo E, Fusco R, D'Amico R, Militi A, Oteri G, Wallace JL, et al. (June 2018). "Anti-inflammatory effect of ATB-352, a H2S -releasing ketoprofen derivative, on lipopolysaccharide-induced periodontitis in rats". Pharmacological Research. 132: 220–231. doi:10.1016/j.phrs.2017.12.022. PMID 29287688. S2CID 12099369.
^ Costa SK, Muscara MN, Allain T, Dallazen J, Gonzaga L, Buret AG, et al. (November 2020). "Enhanced Analgesic Effects and Gastrointestinal Safety of a Novel, Hydrogen Sulfide-Releasing Anti-Inflammatory Drug (ATB-352): A Role for Endogenous Cannabinoids". Antioxidants & Redox Signaling. 33 (14): 1003–1009. doi:10.1089/ars.2019.7884. PMC 7578177. PMID 32064887.

This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it.